Genesys Snapshot:
Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.
Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.
Our team has worked together for two decades of successful and continuous partnership.
Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.
We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.
We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.
Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.
These Genesys portfolio companies both generated huge exits in quick succession.
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 4,666,700 common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The gross proceeds of the Offering to Profound, before deducting the underwriting discounts and commissions and other offering expenses payable by Profound, are expected to be approximately US$35 million.
TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers, a global leader in medical technology, pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution...
TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services (“CMS”) has released its final rule (the “Final Rule”) establishing, for the first time, a Category 1 CPT® code for the Transurethral Ultrasound Ablation (“TULSA”) procedure, effective January 1, 2025.
Quebec City, Canada & Sydney, Australia, October 31 2024 - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC).
ANCOUVER, BC, October 30, 2024 /CNW/ – Kapoose Creek Bio, a biotechnology company leveraging AI for drug discovery from nature, today announced an exclusive license of Adapsyn Bioscience’s preeminent chemical informatics platform, and the acquisition of its state-of-the art drug discovery lab and globally recognized talent.
Bagsværd, Denmark, 20 September 2024 - Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023.
Quebec City and Toronto, Canada, September 4th, 2024 - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced the closure of a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarité FTQ (Fonds).
June 24, 2024 - The past couple of years have seen Big Pharmas whip out their wallets to place high-stake bets in the red-hot races for antibody-drug conjugates, radiopharmaceuticals and obesity drugs, to name a few. We wanted to take another look at some of the deals that have kept our attention.
